Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
ObjectiveTo evaluate the combination of pembrolizumab, cisplatin and gemcitabine in recurrent platinum-resistant ovarian cancer.MethodsPatients received six cycles of chemotherapy with gemcitabine and cisplatin on day 1 and day 8 of a 21-day treatment cycle.Pembrolizumab was administered on day 1 of cycles 3-6 and as maintenance monotherapy in cycl